Search results for "myocardial"

showing 10 items of 1323 documents

0053: Incidence of cardiovascular events following myocardial infarction in France: an observational analysis using a claims database

2016

Objectives To describe the characteristics and treatments of patients having a myocardial infarction (MI) and estimate the incidence of cardiovascular events following the index MI, in the French Health Insurance database. Method A cohort of patients who had a MI in France between 2007 and 2011 was extracted from a claim database: the Echantillon Generaliste de Beneficiaires (a 1% representative sample of subjects covered by the general health insurance (?600,000 patients). The incidence of cardiovascular events following the index MI was estimated using the Kaplan Meier method. Results 1,977 subjects were identified with an index myocardial MI: 2/3 were males, mean age=67.2 y, 20.6% had di…

medicine.medical_specialtybusiness.industryIncidence (epidemiology)medicine.diseaseClopidogrelSurgeryDiabetes mellitusInternal medicineCohortmedicineCumulative incidenceMyocardial infarctionCardiology and Cardiovascular MedicinebusinessStrokeThiazidemedicine.drugArchives of Cardiovascular Diseases Supplements
researchProduct

Long-Term Clinical Outcomes After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Ostial/Midshaft Lesions in Unprotecte…

2014

Objectives The aim of this study was to report the long-term clinical outcomes after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) versus coronary artery bypass grafting (CABG) for ostial/midshaft lesions in an unprotected left main coronary artery (ULMCA). Background Data regarding outcomes in these patients are limited. Methods Of a total of 2,775 patients enrolled in the DELTA multinational registry, 856 patients with isolated ostial/midshaft lesions in an ULMCA treated by PCI with DES (n = 482) or CABG (n = 374) were analyzed. Results At a median follow-up period of 1,293 days, there were no significant differences in the propensity score-adjusted analyses for …

medicine.medical_specialtybusiness.industryIncidence (epidemiology)medicine.medical_treatmentHazard ratioPercutaneous coronary interventionEuroSCOREmedicine.diseaseConfidence intervalSurgerymedicine.anatomical_structureInternal medicineConventional PCImedicineCardiologyMyocardial infarctionbusinessCardiology and Cardiovascular MedicineArteryJACC-Cardiovascular interventions
researchProduct

Platelet Function Changes In Acute Myocardial Infarction

1981

Whether the thrombotic component of myocardial infarction is primary or secondary in a given patient, platelet function alterations can influence many mechanism from which depends if the thrombotic lesion grows or sends platelet emboli to the smaller myocardial vessels. Recently in some cases of infarction, coronary artery spasm has been demonstrated angiographically; thromboxanes, vasoconstrictive and platelet-aggregating substances, are released by platelets during myocardial ischemia. The local release of these substances may modify the myocardial cell viability and regional blood flow.The aim of the present study was to investigate changes in platelet function in relation to the time in…

medicine.medical_specialtybusiness.industryInternal medicineCardiologyMedicinePlateletMyocardial infarctionbusinessmedicine.diseaseFunction (biology)Oral Presentations
researchProduct

P4550Growth differentiation factor 15 as an integrative biomarker of heart failure in patients with acute myocardial infarction

2019

Abstract Background Growth differentiation factor 15 (GDF15), a stress-responsive cytokine member of the transforming growth factor-β family, is an emerging biomarker in cardiovascular (CV) diseases. GDF15 is weakly expressed in normal condition but increased in pathological situations such as inflammation, oxidative stress, and left ventricular remodeling. Recent data suggest GDF15 as a marker in heart failure (HF). Purpose We aimed to identify the determinants of GDF15 circulating levels in patients admitted for an acute myocardial infarction (AMI). Methods In our prospective study, all consecutive patients admitted from June 2016 to February 2018 for type 1 AMI in the Coronary Care unit …

medicine.medical_specialtybusiness.industryInternal medicineHeart failuremedicineCardiologyBiomarker (medicine)In patientMyocardial infarctionCardiology and Cardiovascular Medicinebusinessmedicine.diseaseEuropean Heart Journal
researchProduct

Protein S deficiency and Heerlen polymorphism in a Polish patient with acute myocardial infarction and previous venous thromboembolism

2013

medicine.medical_specialtybusiness.industryInternal medicinemedicineCardiologyHematologyProtein S deficiencyMyocardial infarctionmedicine.diseasebusinessVenous thromboembolism
researchProduct

Innovative Managed Care May Be Related to Improved Prognosis for Acute Myocardial Infarction Survivors

2021

Background: Mortality following discharge in myocardial infarction survivors remains high. Therefore, we compared outcomes in myocardial infarction survivors participating and not participating in a novel, nationwide managed care program for myocardial infarction survivors in Poland. Methods: We used public databases. We included all patients hospitalized due to acute myocardial infarction in Poland between October 1, 2017 and December 31, 2018. We excluded from the analysis all patients aged <18 years as well as those who died during hospitalization or within 10 days following discharge from hospital. All patients were prospectively followed. The primary end point was defined as death …

medicine.medical_specialtybusiness.industryManaged Care ProgramsMyocardial InfarctionPrognosismedicine.diseaseArticleCoronary artery diseasePercutaneous Coronary InterventionInternal medicinemedicineCardiologyHumansManaged careSurvivorsMyocardial infarctionCardiology and Cardiovascular MedicinebusinessCirculation: Cardiovascular Quality and Outcomes
researchProduct

2020

Background Psoriasis is a frequent chronic inflammatory cytokine‐mediated skin disease and was identified to be an independent risk factor for the occurrence of myocardial infarction (MI). However, data about the impact of psoriasis on mortality and other in‐hospital adverse events in the setting of MI are sparse and inconsistent. Methods and Results The nationwide German inpatient sample of the years 2005 to 2016 was used for statistical analysis. Hospitalized patients with MI were stratified for the presence of psoriasis and the impact of psoriasis on in‐hospital events was investigated. Overall, 3 307 703 patients with MI (37.6% females, 56.8% aged ≥70 years) were treated in Germany (20…

medicine.medical_specialtybusiness.industryMortality rateDisease030204 cardiovascular system & hematologymedicine.disease030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicinePsoriasismedicineMyocardial infarctionRisk factorCardiology and Cardiovascular MedicinebusinessJournal of the American Heart Association
researchProduct

Microvascular obstruction in non-STEMI related areas: An uninvited guest in STEMI?

2018

medicine.medical_specialtybusiness.industryMyocardial Infarction030204 cardiovascular system & hematologyCoronary Vessels03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionNon stemiInternal medicinemedicineCardiologyHumansST Elevation Myocardial Infarction030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessInternational journal of cardiology
researchProduct

α-HYDROXYBUTYRIC DEHYDROGENASE IN THE DIAGNOSIS OF MYOCARDIAL INFARCTION

1962

medicine.medical_specialtybusiness.industryMyocardial InfarctionElectrocardiography in myocardial infarctionDehydrogenaseGeneral Medicinemedicine.diseaseCardiovascular DiseasesInternal medicinemedicineCardiologyHumansMyocardial infarctionOxidoreductasesbusinessAgedThe Lancet
researchProduct

Chronic total coronary occlusions and the Occluded Artery Trial. A critical appraisal.

2008

The OAT trial and its angiographic substudy TOSCA-2, along with a number of published commentaries, represents examples of over-interpretation of clinical study results. A study that achieved no statistically significant result for any of the study endpoints can only claim to have proven that their null hypothesis cannot be rejected. The lack of power due to a reduction of patient numbers by one third, and an unexpected low event rate, makes it not unlikely that another trial would be able to disprove the null hypothesis. These statistical facts should be accepted by the authors and commentators. Instead, the inconclusive results were interpreted in such a way that they might apply to patie…

medicine.medical_specialtybusiness.industryMyocardial Infarctionocclusions.Critical appraisalmedicine.anatomical_structureCoronary OcclusionInternal medicinemedicineCardiologyHumansChronicCardiology and Cardiovascular MedicinebusinesscoronaryRandomized Controlled Trials as TopicArteryEuroIntervention
researchProduct